Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
← catalyst calendarNCT07474792 · readout ≤ 438 d
Sponsored by Oruka Therapeutics, Inc. (industry) · ORKA — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
160estimated
Sites
39
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-19 | actual | When the study began enrolling |
| Primary completion | Oct 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Plaque Psoriasis
Interventions
- Drug: ORKA-002
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFProportion of Participants Achieving 100% Reduction in PASI Score at Week 16
measured Week 16
Incidence of Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse events (TEAEs) and TEAEs of of Special Interest (TEAESIs)
measured Day 1 through Week 48
Permalink · ORKA's whole pipeline · Catalyst calendar · Every registered study · What changed